echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > China's cardiovascular disease patients reached 330 million, related prevention and control, drug prices are concerned

    China's cardiovascular disease patients reached 330 million, related prevention and control, drug prices are concerned

    • Last Update: 2020-11-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    "Pharmaceutical Network Industry Dynamics" This year's September 29th, the 21st World Heart Day, this year's theme is "Love with Heart".
    At present, cardiovascular disease has become a serious threat to the health of China's residents a major "killer", the National Cardiovascular Center in 2019 statistics show that China's annual cardiac death rate of up to 550,000, according to the 2019 China Cardiovascular Health and Disease Report, the number of cardiovascular disease patients in China has reached 330 million.
    study showed that obesity, smoking, physical indulation, unhealthy eating habits and so on are the main factors that cause cardiovascular disease.
    people need to protect heart health, healthy diet, adhere to exercise, more critical is to do a good job in the prevention and control of cardiovascular diseases.
    years, China's relevant departments attach great importance to cardiovascular disease prevention and control work.
    Health China Action (2019-2030) gives specific instructions for the prevention and treatment of cardiovascular diseases, and clearly promotes the "three high" co-management, to carry out overweight obesity, blood pressure and blood sugar increase, blood lipid abnormalities and other high-risk groups of disease risk assessment and intervention guidance, do a good job of hypertension, diabetes, blood lipid abnormal standardized management.
    of this year, the State Health Insurance Administration issued the Guidance on establishing and improving the mechanism for the protection of basic medical insurance outpatients for workers (draft for comments) and solicited opinions from the public.
    in this draft, to enhance the function of outpatient co-care protection.
    , starting with high blood pressure, diabetes and other chronic outpatient diseases, and gradually bring the general outpatient medical expenses of frequent and common diseases into the scope of payment of the co-ordination fund.
    drug price is a very important concern for patients with cardiovascular and cerebrovascular diseases.
    because cardiovascular disease is a chronic disease, need to adhere to long-term medication, patient compliance is very important, good drug habits help regulate treatment.
    for most patients, the cost of the drug is often a burden, and some patients find it difficult to stick to it.
    With the expansion of drug belt procurement, the second batch of collection, the third batch of collection and other policies, the scope of collection and selection of varieties continue to increase, including some common cardiovascular drugs, such as Ebersatan hydrochlorochlorophenicol tablets, hydrochlorochloride tablets, these selected drugs in order to ensure quality at the same time, the price has been significantly reduced, will be conducive to reducing the burden of patients, while improving patient compliance.
    especially after the price of some original drugs fell, not only can effectively reduce the burden of drug costs in the process of use, but also can make patients better follow the doctor's advice, do a good job of slow disease prevention and control.
    recently released the "2020 National Health Insurance Drug Catalog adjustment through the form of examination of the list of declared drugs", it is not difficult to see the shadow of the "three high" drugs, many of which have just been approved for the market of innovative drugs shortlisted, it can be seen that China's "three high" patients concern.
    when more good medicine into health insurance, it is expected to further reduce the "three high" patients' drug burden, improve the quality of life of patients.
    industry believes that China's high blood pressure and diabetes control has achieved a lot of results.
    , treatment and management remain weak in terms of screening.
    , the public's lack of attention to lipid control is a major short plate of cardiovascular prevention, which requires the promotion of chronic disease management and early intervention.
    in addition to treatment, there is also a need to focus on the clinical value of innovative drugs to meet the needs of patients with cardiovascular diseases.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.